Article By:
Than Merrill
Saturday, September 23, 2023 5:18 PM EDT
You’ve probably heard the term 'housing bubble' thrown around in conversations about the real estate market, especially in the context of sharp price increases and potential downturns. But do you truly understand what it means?
Read
Article By:
Erik Conley
Saturday, September 23, 2023 4:59 PM EDT
In this weekly market report, we will take a look at the various asset classes, industries, equity categories, and exchange-traded funds that moved the market higher, as well as the market segments that defied the trend by moving lower.
In this article: CAMP, TSLA, SIVR, SPX, MSOS, MLKN
Read
Article By:
FXStreet
Saturday, September 23, 2023 4:39 PM EDT
The gold price recovered some ground on Friday after hitting a weekly low of $1913.99. Factors like dropping US T-bond yields and an upbeat market sentiment drove XAU/USD’s price toward the $1924.56 mark, achieving gains of 0.25%.
In this article: UUP, XAU
Read
Article By:
Zacks Investment Research
Saturday, September 23, 2023 4:18 PM EDT
In a turn of events, the United Kingdom’s Competition and Markets Authority now views Microsoft’s restructured deal to acquire game developer Activision Blizzard as a positive for the nation's merger and acquisition sector.
In this article: ATVI, MSFT Also: UBSFY, AAPL
Read
Video By:
Ernie Varitimos
Saturday, September 23, 2023 3:59 PM EDT
In this brief video, I delve into the world of zero day to expiry trading as I reveal the nuances of the out-of-the-money butterfly trade.
In this video: VIX
Watch
Article By:
Tim Knight
Saturday, September 23, 2023 3:39 PM EDT
I’ve never traded Upstart Holdings before, but I bought puts on it this week, based on its very clean head-and-shoulders pattern. So what? Well, this is unusual, because the stock has already been ravaged.
In this article: UPST
Read
Article By:
Graham Summers
Saturday, September 23, 2023 3:29 PM EDT
In very simple terms, the Fed sent a message that rates will need to be higher for longer to end inflation. The markets took the news hard, with bonds, stocks, and even oil all selling off simultaneously this week.
In this article: TLT, SPX
Read
Article By:
Roman Butko
Saturday, September 23, 2023 3:19 PM EDT
In previous reviews, we extensively discussed the verbal interventions made by Japanese officials who aim to bolster the yen through their public statements. This time, similar actions have been taken by FOMC officials, led by Jerome Powell.
In this article: FXE, FXB, FXY, UUP, BITCOMP
Read
Article By:
Bespoke Investment Group
Saturday, September 23, 2023 2:59 PM EDT
Friday marked the 265th day of the year, meaning there are just 99 days left in what still seems like a new year. Heading into the home stretch, the market looked tired as stocks erased much of the gains they posted in the spring/summer rally.
In this article: SPX
Read
Article By:
AllAboutAlpha
Saturday, September 23, 2023 2:39 PM EDT
Preqin recently published the results of its institutional investor survey, which focused on private fund fee terms and conditions. The results showed that transparency around fees, rather than the amount of fees charged, were of primary concern.
Read
2023 Q3 is expected to be the last period of declining earnings for the index, with positive growth resuming from 2023 Q4 onwards.
Market volatility has been remarkably low in 2023, apart from the brief shock following the failure of Silicon Valley Bank earlier this year.
The longer inflation stays higher, the more power unions have. And the more power unions have, the more momentum inflation has.
Investing in the artificial intelligence (AI) sector should generate fantastic returns over the next decade but most people are not investing in it the best way.
The drop in treasury bonds is telling us not to expect a change anytime soon. Based on Thursday's price action, it is reasonable to expect higher interest rates to continue.
Over the past year, UBS’s share price rose about 59% from $16.14 to $25.66 as of Thursday’s market close.
Extensive research on NDDs has uncovered a different treatment pathway that's enabling some biotechnology firms to target more than one NDD with the same drug candidate.
